65,437 trials
Infections, Rotavirus · Rotavirus Vaccines
Primary: Number of Seroconverted Subjects for Anti-rotavirus (Anti-RV) Immunoglobulin A (IgA) Antibody — 84 Subjects
Obesity · Impaired Glucose Tolerance
Primary: Change in Weight — -2.49; 0.43 kilograms
Persistent Asthma
Primary: Standardized Baseline-Adjusted Trough Morning Forced Expiratory Volume in One Minute (FEV1) Area Under the Effect Curve From Time Zero to 6 Weeks (AUEC(0-6wk)) — 62…
HER2-mutant Non-Small Cell Lung Cancer
Primary: Objective Response Rate (ORR) — 0; 6 Participants
Rheumatoid Arthritis
Primary: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 — 198; 207 participants
Injury as a Result of Positioning
Primary: Percentage of Participants With 20+% Cerebral Desaturation Events — 40; 40 Participants
Verruca, Warts
Primary: Size of Verrucae (Warts) — 2.333; 3.889 millimeters — p=0.383
Diabetes Mellitus
Primary: Change in HbA1c From Baseline to Week 28 — -1.39; -1.98; -1.60 % HbA1c — p=0.003
Heroin Dependence
Primary: Drug Self-administration — 350; 255; 223; 113 Clicks on a computer mouse
Acute Myeloid Leukemia · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities · Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Primary: Maximum Tolerated Dose of Clofarabine — 25 mg/m^2 of clofarabine
Prostate Cancer
Primary: Pre/Post Ratio PSA Area Under the Curve (AUC) — 0.57; 0.61 Ratio
Coronary Artery Disease · Angina Pectoris · Cardiac Valve Disease
Primary: Sternal Healing Score at 3 Month Post op, as Defined by a 6-point Scale to Evaluate Bone Healing — 1.8; 2.6 units on a scale — p=<0.0001
Meibomian Gland Dysfunction
Primary: Percentage of Meibum Quality Responders in the Study Eye — 46.3; 33.9; 32.1; 42.9 Percentage of Patients
Transtibial Amputation - Unilateral
Primary: Peak Ankle Dorsiflexion During Stance — 18.871; 22.023; 18.657; 22.016 degrees
Renal Anemia
Primary: Change in Average Hb Concentration Between Baseline and Evaluation Period — 11.26; 11.08; -0.78; -0.15 g/dL